Navigator

      Support By : Li-lab

Drugs And Genes
Negative Drug Target Genes
GENE_SYMBOL DRUG_NAME Ki (nM) IC50 (nM) Kd (nM) EC50 (nM) Potency (nM) AC50 (nM) Datasource
PRKCA 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol;hydrochloride NA 466000 NA NA NA NA TTD
PRKCA N-[5,21-dihydroxy-12,14-dioxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]formamide NA 200000 NA NA NA NA TTD
PRKCA 13-Amino-5,21-dihydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione NA 200000 NA NA NA NA TTD
PRKCA (5Z)-5-{[5-(2-chloro-5-nitrophenyl)furan-2-yl]methylidene}-1-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione NA 205160 NA NA NA NA BindingDB
PRKCA Phorbol 12-myristate 13-acetate NA NA NA 1700000 NA NA BindingDB|PubChem
PRKCA N-(3-nitrophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonamide NA 165000 NA NA NA NA BindingDB
PRKCA Paroxetine NA 220000 NA NA NA NA BindingDB|TTD
PRKCA 13-(Ethylamino)-5,21-dihydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione NA 200000 NA NA NA NA TTD
PRKCA 13-(1,3-Dihydroxypropan-2-ylamino)-5,21-dihydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione NA 200000 NA NA NA NA TTD
PRKCA [5,21-Dihydroxy-12,14-dioxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]urea NA 200000 NA NA NA NA TTD
PRKCA 5,21-Dihydroxy-13-(2-hydroxyethylamino)-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione NA 200000 NA NA NA NA TTD
PRKCA 3-[[5,21-Dihydroxy-12,14-dioxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]amino]propanenitrile NA 200000 NA NA NA NA TTD
PRKCA 2-[[5,21-Dihydroxy-12,14-dioxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]amino]acetic acid NA 110000 NA NA NA NA BindingDB|TTD
PRKCA N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)acetamide NA 500000 NA NA NA NA BindingDB|TTD
PRKCA N-[5,21-dihydroxy-12,14-dioxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]-2-(dimethylamino)acetamide NA 200000 NA NA NA NA TTD
PRKCA N-[5,21-dihydroxy-12,14-dioxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]-2-hydroxyacetamide NA 200000 NA NA NA NA TTD
PRKCA 13-(2,3-Dihydroxypropylamino)-5,21-dihydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione NA 200000 NA NA NA NA TTD
PRKCA N-[5,21-dihydroxy-12,14-dioxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]acetamide NA 130000 NA NA NA NA BindingDB|TTD
PRKCA N-[5,21-dihydroxy-12,14-dioxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]methanesulfonamide NA 200000 NA NA NA NA TTD
PRKCA Acetic acid (2S,3R)-2-hydroxymethyl-5-oxo-tetrahydro-furan-3-yl ester 1700000 NA NA NA NA NA TTD